Author:
Rieser Caroline J.,Zenati Mazen,Narayanan Sowmya,Bahary Nathan,Lee Kenneth K.,Paniccia Alessandro,Bartlett David L.,Zureikat Amer H.
Funder
National Cancer Institute
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA A Cancer J Clin. 2020;70(1):7–30. https://doi.org/10.3322/caac.21590.
2. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21. https://doi.org/10.1158/0008-5472.Can-14-0155.
3. Howlader N, Noone A, Krapcho M, Miller D, Brest A, Yu M, et al. (eds). SEER Cancer Statistics Review, 1975–2016. National Cancer Institute. https://seer.cancer.gov/csr/1975_2016/. Accessed Jan 2021.
4. Groot VP, Gemenetzis G, Blair AB, et al. Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg. 2019;269(6):1154–62. https://doi.org/10.1097/sla.0000000000002734.
5. Neuhaus P, Riess H, Post S, et al. CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation in patients with resected pancreatic cancer (PC). J Clin Oncol. 2008;26(15 Suppl):LBA4504. https://doi.org/10.1200/jco.2008.26.15_suppl.lba4504.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献